70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.

Abstract

Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) (n=79) or docetaxel (DOC) (n=55) was investigated in the neoadjuvant setting for breast cancer patients. Sensitivity of breast tumors to PAC, but not to DOC, was found to be significantly associated with ER negativity (P=0.003), PR negativity (P=0.007), and Ki67 positivity (P=0.007). Breast tumors classified into the responders by 70-GC showed a significantly (P=0.005) higher reduction rate to PAC and interestingly a significantly (P=0.009) lower reduction rate to DOC than those classified into the non-responders by 70-GC, suggesting that 70-GC might be useful for the differentiation of PAC-sensitive and DOC-sensitive breast tumors.

• Authors: Y Naoi, T Tanei, K Kishi, R Tsunashima, N Tominaga, Y Baba, T Nakayama, K Shimazu, S J Kim, Y Tamaki, S Noguchi
• Journal: Cancer letters (Cancer Lett) Vol. 314 Issue 2 Pg. 206-12 (Jan 28 2012) ISSN: 1872-7980 [Electronic] Ireland
• PMID: 22018777 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents, Phytogenic
• Ki-67 Antigen
• Receptors, Estrogen
• Receptors, Progesterone
• Taxoids
• Docetaxel
• ERBB2 protein, human
• Receptor, ErbB-2
• Paclitaxel

Topics

• Antineoplastic Agents, Phytogenic (therapeutic use)
• Breast Neoplasms (classification, drug therapy, genetics, pathology)
• Docetaxel
• Female
• Gene Expression Profiling
• Humans
• Ki-67 Antigen (analysis)
• Paclitaxel (therapeutic use)
• Receptor, ErbB-2 (analysis)
• Receptors, Estrogen (analysis)
• Receptors, Progesterone (analysis)
• Taxoids (therapeutic use)